Dr G Ranga Raman

Dr G Ranga Raman works with a skilled oncology team and uses modern treatment facilities at Medicover Cancer Institute, Nellore, to provide safe, reliable, and high-quality cancer care. Whether you need a consultation, chemotherapy, blood cancer treatment, or transplant support, you can trust his experience and approach.

If you are looking for a caring and experienced medical oncologist in Nellore, book an appointment with Dr G. Ranga Raman and receive clear guidance and compassionate care throughout your cancer journey.

Past Experience

• Medicover Cancer Institute: Medical Oncology, Senior Consultant (2021 to present)
• HCG Curie Cancer Centre: Medical Oncology, Head of Department (2015-2021)
• NIMS Medical Oncology: DM Resident (2013-2015)
• BIACRI: Medical Oncology, Jr. Consultant (2012-2012)
• NRSMCH: Hematology, PDT (2011 - 2011)
• SGPGI: Hematology, PDT(2010 - 2010)

Awards & Achievements

• Second prize in debate on stem cell therapy (against) at ICAMCON 2009, Hyderabad (National conference)
• First prize for the best abstract from India in Best of ASCO 2014, Hyderabad (National conference) “Outcomes in pediatric CML in a developing country - Beyond the disease biology”
• American Society of Hematology Best Abstract Achievement Award for the in ASH 2014, San Francisco for the abstract “Effectiveness in predicting the response and outcome with three prognostic scoring systems in pediatric CML CP on upfront Imatinib: Results of a retrospective study from single center”

Clinical Trial Experience As Principal Investigator (PI)

• A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Trans arterial Chemoembolization (TACE) in combination with either Durvalumab Monotherapy or Durvalumab Plus Bevacizumab therapy in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-1)
• A double-blinded extension study to provide adjuvant treatment with single agent Herceptin®️ or TX05 and assess continued safety and immunogenicity in subjects with HER2-positive early breast cancer following neoadjuvant treatment and surgical resection in Protocol TX05-03”
• A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase III Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
• A Prospective, Randomized, Multicenter, comparative, open-label Parallel Study to evaluate the Efficacy, safety and Pharmacokinetics of Test-Trastuzumab Emtansine (ZRC-3256; Cadila HealthCare Limited) and Reference - Trastuzumab Emtansine (Kadcyla , a product of Roche ) in HER2-Positive Metastatic Breast Cancer Patients
• A phase III randomized double-blind, placebo-controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment

Memberships

• ASCO
• ESMD
• ASH
• MOSAP
• ISO